Navigation Links
Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex
Date:5/30/2008

Isolagen Intends to Appeal Action

EXTON, Pa., May 30 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) today announced that on May 29, 2008 it received notice from the staff of the American Stock Exchange (AMEX) indicating that, in the staff's opinion, the Company's plan of compliance did not demonstrate its ability to regain compliance with the Exchange's continued listing standards set forth in Sections 1003 (a)(i)-(iii) of the AMEX Company Guide within the prescribed time period, and, therefore, that its common stock is subject to being delisted from the Exchange. As discussed in the Company's Form 8-K dated March 14, 2008 and in Item 1A. of the Company's Form 10-Q for the quarter ended March 31, 2008, the Company had initially received a non-compliance notice from the staff of the AMEX on March 12, 2008, and had submitted a plan of compliance to the AMEX on April 14, 2008.

Isolagen intends to appeal this determination and will request a hearing before a committee of the Exchange. There can be no assurance that the Company's request for continued listing will be granted after such hearing.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) L
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Isolagen, Inc. Sells Switzerland Facility
2. Isolagen, Inc. Promotes Todd Greenspan to Chief Financial Officer (CFO)
3. Isolagen, Inc. Receives Notification Letter from American Stock Exchange
4. Isolagen, Inc. Postpones Annual Meeting
5. Chem Rx Corporation Reports First Quarter 2008 Financial Results
6. CRH Medical reports Q1 2008 results
7. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
8. Unilens Vision Reports Increased Royalty Income
9. China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008
10. Shamir Optical Industry Ltd. Reports First Quarter 2008 Results
11. Nyer Medical Group, Inc. Reports Revenues of $18.9 Million With Net Loss of $.16 Per Share for 3rd Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3More Preemies Born Among the Poor 62390 1More Preemies Born Among the Poor 62390 2ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 62385 1ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 62385 2ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 62385 3Rate of Confirmed AIDS in Prison 2 5 Times the Rate in the U S General Population 62380 1Rate of Confirmed AIDS in Prison 2 5 Times the Rate in the U S General Population 62380 2Rate of Confirmed AIDS in Prison 2 5 Times the Rate in the U S General Population 62380 3